Skip to main content

DISEÑO Y SINTESIS DE INHIBIDORES ALOSTERICOS DE CXCR4 Y DEGRADADORES DE IRAK4 COMO POTENCIAL TRATAMIENTO DE LIMFOMA DE CELULAS B

PID2021-123039OB-C22

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT RAMON LLULL, FUNDACIO PRIVADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miguel|||0000-0003-0597-5811
  • Sàrrias, Lluís
  • Gorjón-de-Pablo, Gema
  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Camaló-Vila, Judith|||0000-0003-2692-5952
  • Gibert, Albert
  • Puig de la Bellacasa, Raimon|||0000-0001-8349-4082
  • Teixidó, Jordi|||0000-0002-2720-9811
  • Roué, Gaël|||0000-0003-0245-2257
  • Borrell, José I.|||0000-0001-9409-2919
  • Estrada-Tejedor, Roger|||0000-0002-2983-0492
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miquel
  • Sàrrias, Lluís
  • Gorjón de Pablo, Gema
  • Fernández-Serrano, Miranda
  • Camaló Vila, Judith
  • Puig de la Bellacasa, Raimon
  • Teixidó, Jordi
  • Roué, Gaël
  • Borrell, Jose I.
  • Estrada-Tejedor, Roger
  • Gibert-Bosch, Albert
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

  • Martínez-Asensio, Miquel
  • Sàrrias, Lluís
  • Gorjón de Pablo, Gema
  • Fernández-Serrano, Miranda
  • Camaló Vila, Judith
  • Puig de la Bellacasa, Raimon
  • Teixidó, Jordi
  • Roué, Gaël
  • Borrell, Jose I.
  • Estrada-Tejedor, Roger
  • Gibert-Bosch, Albert
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played a pivotal role in the identification of new active compounds. But, has its golden age ended? A virtual library of 450,000 tetraamines of general structure 8 was constructed by using five spacers and 300 diamines, which were obtained from the corresponding commercially available cyclic amines. Diversity selection was performed to guide the virtual screening of the former database and to select the most representative set of compounds. Molecular docking on the CXCR4 crystal structure allowed us to rank the selection and identify those candidate molecules with potential antitumor activity against diffuse large B-cell lymphoma (DLBCL). Among them, compound A{17,18} stood out for being a non-symmetrical structure, synthetically feasible, and with promising activity against DLBCL in in vitro experiments. The focused study of symmetrical-related compounds allowed us to identify potential pre-hits (IC50~20 µM), evidencing that molecular design is still relevant in the development of new CXCR4 inhibitor candidates., info:eu-repo/semantics/publishedVersion